Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16095397 | 0.91 | KLK5 (0.51) | CTSSCTSKKLK5CTSBNOS2 | |
| SCHEMBL16095400 | 0.91 | KLK5 (0.51) | CTSSCTSKKLK5CTSBNOS2 | |
| SCHEMBL4832114 | 0.90 | CTSS (0.47) | CTSSCTSKKLK5ECE1CTSB | |
| SCHEMBL4832110 | 0.90 | CTSS (0.47) | CTSSCTSKKLK5ECE1CTSB | |
| SCHEMBL4831502 | 0.88 | KLK5 (0.48) | CTSSCTSKKLK5CTSBBCL2 | |
| SCHEMBL4833191 | 0.88 | KLK5 (0.48) | CTSSCTSKKLK5CTSBBCL2 | |
| SCHEMBL14885705 | 0.87 | CTSS (0.54) | CTSSCTSKKLK5CTSBBCL2 | |
| SCHEMBL14885702 | 0.87 | CTSS (0.54) | CTSSCTSKKLK5CTSBBCL2 | |
| SCHEMBL2262214 | 0.84 | KLK5 (0.51) | CTSSCTSKKLK5CTSBNOS2 | |
| SCHEMBL31758542 | 0.84 | KLK5 (0.51) | CTSSCTSKKLK5CTSBNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | CTSS 459/4885CTSK 342/4885KLK5 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.